$ENTA
ENANTA PHARMACEUTICALS INC Stock $enta

$enta Overview Financials Valuation SEC Filings Company Website

2021 Q3 Form 10-K Financial Statement

#000095017021004895 Filed on November 24, 2021

Income Statement

Concept	2021 Q3	2021	2020 Q3
Revenue	$23.58M	$97.07M	$23.63M
YoY Change	-0.23%	-20.74%	-53.95%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$8.356M	$32.54M	$6.730M
YoY Change	24.16%	18.74%	9.25%
% of Gross Profit
Research & Development	$48.95M	$174.1M	$36.69M
YoY Change	33.4%	27.32%	-5.24%
% of Gross Profit
Depreciation & Amortization	$806.0K	$3.334M	$900.0K
YoY Change	-10.44%	-8.41%	1.12%
% of Gross Profit
Operating Expenses	$57.30M	$174.1M	$43.41M
YoY Change	32.0%	27.32%	-3.28%
Operating Profit		-$109.6M
YoY Change		163.15%
Interest Expense	$333.0K	$2.021M	$1.150M
YoY Change	-71.04%	-68.77%	-49.34%
% of Operating Profit
Other Income/Expense, Net		$1.994M
YoY Change		-69.88%
Pretax Income	-$33.39M	-$107.6M	-$18.63M
YoY Change	79.25%	207.2%	-313.89%
Income Tax	-$8.795M	-$28.58M	$10.71M
% Of Pretax Income
Net Earnings	-$24.60M	-$79.00M	-$29.34M
YoY Change	-16.16%	118.41%	-419.23%
Net Earnings / Revenue	-104.34%	-81.38%	-124.16%
Basic Earnings Per Share		-$3.92
Diluted Earnings Per Share	-$1.217M	-$3.92	-$1.462M
COMMON SHARES
Basic Shares Outstanding		20.17M
Diluted Shares Outstanding		20.17M

Balance Sheet

Concept	2021 Q3	2021	2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$244.0M	$244.0M	$386.6M
YoY Change	-36.89%	-36.89%	15.34%
Cash & Equivalents	$57.21M	$57.21M	$87.13M
Short-Term Investments	$186.8M	$186.8M	$299.5M
Other Short-Term Assets	$14.19M	$14.19M	$26.70M
YoY Change	-46.86%	-46.86%	74.51%
Inventory
Prepaid Expenses
Receivables	$23.58M	$23.58M	$23.49M
Other Receivables	$37.26M	$37.26M	$0.00
Total Short-Term Assets	$319.0M	$319.0M	$436.8M
YoY Change	-26.97%	-26.96%	8.71%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.943M	$10.65M	$8.596M
YoY Change	-30.86%	-31.71%	-21.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$108.4M	$108.4M	$32.60M
YoY Change	232.56%	232.56%	-49.85%
Other Assets	$92.00K	$700.0K	$92.00K
YoY Change	0.0%	-30.0%	0.0%
Total Long-Term Assets	$119.8M	$119.8M	$49.30M
YoY Change	142.97%	142.94%	-43.97%
TOTAL ASSETS
Total Short-Term Assets	$319.0M	$319.0M	$436.8M
Total Long-Term Assets	$119.8M	$119.8M	$49.30M
Total Assets	$438.8M	$438.8M	$486.1M
YoY Change	-9.74%	-9.73%	-0.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.540M	$9.540M	$5.737M
YoY Change	66.29%	67.37%	-14.23%
Accrued Expenses	$22.43M	$26.63M	$14.16M
YoY Change	58.41%	44.74%	-11.06%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$36.17M	$36.17M	$24.16M
YoY Change	49.74%	49.47%	6.85%
LONG-TERM LIABILITIES
Long-Term Debt	$1.506M	$1.506M	$1.500M
YoY Change	0.4%	0.4%	-16.67%
Other Long-Term Liabilities	$558.0K	$1.684M	$1.078M
YoY Change	-48.24%	-65.63%	-65.23%
Total Long-Term Liabilities	$558.0K	$3.190M	$1.078M
YoY Change	-48.24%	-50.16%	-65.23%
TOTAL LIABILITIES
Total Short-Term Liabilities	$36.17M	$36.17M	$24.16M
Total Long-Term Liabilities	$558.0K	$3.190M	$1.078M
Total Liabilities	$39.36M	$39.36M	$30.55M
YoY Change	28.84%	28.63%	11.76%
SHAREHOLDERS EQUITY
Retained Earnings	$48.58M		$127.6M
YoY Change	-61.92%		-22.09%
Common Stock	$351.2M		$327.2M
YoY Change	7.36%		9.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$399.4M	$399.4M	$455.6M
YoY Change
Total Liabilities & Shareholders Equity	$438.8M	$438.8M	$486.1M
YoY Change	-9.74%	-9.73%	-0.75%

Cashflow Statement

Concept	2021 Q3	2021	2020 Q3
OPERATING ACTIVITIES
Net Income	-$24.60M	-$79.00M	-$29.34M
YoY Change	-16.16%	118.41%	-419.23%
Depreciation, Depletion And Amortization	$806.0K	$3.334M	$900.0K
YoY Change	-10.44%	-8.41%	1.12%
Cash From Operating Activities	-$21.02M	-$70.00M	-$15.46M
YoY Change	35.97%	-1087.53%	-280.82%
INVESTING ACTIVITIES
Capital Expenditures	-$33.00K	$750.0K	-$330.0K
YoY Change	-90.0%	-48.1%	10.0%
Acquisitions
YoY Change
Other Investing Activities	$72.72M	$37.74M	$2.840M
YoY Change	2460.42%	77.35%	-105.47%
Cash From Investing Activities	$72.68M	$36.99M	$2.500M
YoY Change	2807.32%	86.54%	-104.79%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	943.0K	3.080M	230.0K
YoY Change	310.0%	-65.71%	-66.18%
NET CHANGE
Cash From Operating Activities	-21.02M	-70.00M	-15.46M
Cash From Investing Activities	72.68M	36.99M	2.500M
Cash From Financing Activities	943.0K	3.080M	230.0K
Net Change In Cash	52.61M	-29.93M	-12.73M
YoY Change	-513.24%	-183.35%	-70.37%
FREE CASH FLOW
Cash From Operating Activities	-$21.02M	-$70.00M	-$15.46M
Capital Expenditures	-$33.00K	$750.0K	-$330.0K
Free Cash Flow	-$20.99M	-$70.75M	-$15.13M
YoY Change	38.72%	-1353.69%	-270.96%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
CY2020Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001177648
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-09-30
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-35839
CY2021	dei	Entity Registrant Name EntityRegistrantName	ENANTA PHARMACEUTICALS, INC
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-3205099
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	500 Arsenal Street
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Watertown
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02472
CY2021	dei	City Area Code CityAreaCode	617
CY2021	dei	Local Phone Number LocalPhoneNumber	607-0800
CY2021	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
CY2021	dei	Trading Symbol TradingSymbol	ENTA
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q1	dei	Entity Public Float EntityPublicFloat	864668968
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	20324795
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	57206000
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	87131000
CY2021Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	186796000
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	299518000
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	23576000
CY2020Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	23492000
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	14188000
CY2020Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	13655000
CY2021Q3	us-gaap	Income Tax Receivable IncomeTaxReceivable	37255000
CY2020Q3	us-gaap	Income Tax Receivable IncomeTaxReceivable	13041000
CY2021Q3	us-gaap	Assets Current AssetsCurrent	319021000
CY2020Q3	us-gaap	Assets Current AssetsCurrent	436837000
CY2021Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	108416000
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	32634000
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5943000
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8596000
CY2020Q3	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	345000
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4711000
CY2020Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7020000
CY2021Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	608000
CY2020Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	608000
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	92000
CY2020Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	92000
CY2021Q3	us-gaap	Assets Assets	438791000
CY2020Q3	us-gaap	Assets Assets	486132000
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	9540000
CY2020Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	5737000
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	22429000
CY2020Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14159000
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4203000
CY2020Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4261000
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	36172000
CY2020Q3	us-gaap	Liabilities Current LiabilitiesCurrent	24157000
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1126000
CY2020Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3838000
CY2021Q3	enta	Non Convertible Preferred Stock Liabilities NonConvertiblePreferredStockLiabilities	1506000
CY2020Q3	enta	Non Convertible Preferred Stock Liabilities NonConvertiblePreferredStockLiabilities	1479000
CY2021Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	558000
CY2020Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1078000
CY2021Q3	us-gaap	Liabilities Liabilities	39362000
CY2020Q3	us-gaap	Liabilities Liabilities	30552000
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20238000
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20238000
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20077000
CY2020Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20077000
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	202000
CY2020Q3	us-gaap	Common Stock Value CommonStockValue	201000
CY2021Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	351033000
CY2020Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	326963000
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-382000
CY2020Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	844000
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	48576000
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	127572000
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	399429000
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	455580000
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	438791000
CY2020Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	486132000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	97074000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	122473000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	205197000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	174111000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	136756000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	142213000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	32536000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	27356000
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	26246000
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	206647000
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	164112000
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	168459000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-109573000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-41639000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	36738000
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	2021000
CY2020	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	6471000
CY2019	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	8819000
CY2021	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	-27000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-36168000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	46383000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6620000
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	8819000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-107579000
CY2020	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	149000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1994000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-35019000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	45557000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-28583000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1149000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-826000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-78996000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-36168000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	46383000
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.92
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.81
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.37
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.92
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.81
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.21
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20171000
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19940000
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19584000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20171000
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19940000
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20968000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-78996000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	388000
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	173000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1226000
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	698000
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	544000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1226000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	698000
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	544000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-80222000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-35470000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	46927000
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	393679000
CY2019	enta	Stock Issued During Period Value Stock Options And Warrants Exercised StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised	6848000
CY2019	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-4188000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	19226000
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	544000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	46383000
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	462492000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	10481000
CY2020	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-1498000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	19575000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	698000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-36168000
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	455580000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3614000
CY2021	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-534000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	20991000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1226000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-78996000
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	399429000
CY2021	us-gaap	Profit Loss ProfitLoss	-78996000
CY2020	us-gaap	Profit Loss ProfitLoss	-36168000
CY2019	us-gaap	Profit Loss ProfitLoss	46383000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	20991000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	19575000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	19226000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3334000
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3644000
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3258000
CY2021	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	345000
CY2020	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	10608000
CY2019	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-3138000
CY2021	enta	Premium On Marketable Securities PremiumOnMarketableSecurities	4028000
CY2020	enta	Premium On Marketable Securities PremiumOnMarketableSecurities	3575000
CY2019	enta	Premium On Marketable Securities PremiumOnMarketableSecurities	1491000
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-2116000
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-304000
CY2019	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	4336000
CY2021	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	-27000
CY2020	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	149000
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	97000
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	51000
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-25000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	84000
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-27821000
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-15892000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	533000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7270000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1929000
CY2021	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	24214000
CY2020	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	4127000
CY2019	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	8916000
CY2021	enta	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-5418000
CY2020	enta	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-3184000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3774000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-883000
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1791000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	8350000
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1368000
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	5750000
CY2019	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-1388000
CY2021	enta	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-5879000
CY2020	enta	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-3535000
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-520000
CY2020	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-922000
CY2019	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	291000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-69996000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	7088000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	71418000
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	307348000
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	338553000
CY2019	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	549312000
CY2021	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	345089000
CY2020	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	359828000
CY2019	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	468065000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	750000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1445000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5417000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	36991000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	19830000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-86664000
CY2021	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	3614000
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	51838000
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	32000
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	105000
CY2019	us-gaap	Income Taxes Paid IncomeTaxesPaid	12672000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	137000
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	188000
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	320000
CY2020	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	10481000
CY2019	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	6848000
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	534000
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1498000
CY2019	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	4188000
CY2019	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	86000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3080000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8983000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2574000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-29925000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	35901000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-12672000
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	87739000
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	51838000
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	64510000
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	57814000
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	87739000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3320000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3053000
CY2021	us-gaap	Nature Of Operations NatureOfOperations	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1. Nature of the Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.2241666666666668;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Enanta Pharmaceuticals, Inc. (the “Company”), incorporated in Delaware in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1995</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, is</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> a biotechnology company that uses its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. The Company discovered glecaprevir, the second of two protease inhibitors discovered and developed through its collaboration with AbbVie for the treatment of chronic hepatitis C virus, or HCV. Glecaprevir is co-formulated as part of AbbVie’s leading direct-acting antiviral, or DAA, combination treatment for HCV, which is marketed under the tradenames MAVYRET</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">®</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (U.S.) and MAVIRET</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">®</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (ex-U.S.) (glecaprevir/pibrentasvir). </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Royalties from the Company’s AbbVie collaboration and its existing financial resources provide funding to support the Company’s wholly-owned research and development programs</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, which are primarily focused on the following disease targets: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">respiratory syncytial virus (“RSV”), hepatitis B virus (“HBV”), SARS-CoV-2, and human metapneumovirus (“hMPV”).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.2241666666666668;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is subject to many of the risks common to companies in the biotechnology industry, including but not limited to, the uncertainties of research and development, competition from technological innovations of others, dependence on collaborative arrangements, protection of proprietary technology, dependence on key personnel and compliance with government regulation. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approvals, prior to commercialization. These efforts require significant amounts of capital, adequate personnel and infrastructure, and extensive compliance reporting capabilities.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.2241666666666668;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">COVID-19</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.2241666666666668;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2020, the World Health Organization declared COVID-19 a global pandemic and countries worldwide implemented various measures to contain the spread of the virus. National, state and local governments in affected regions have implemented and may continue to implement safety precautions, including quarantines, border closures, increased border controls, travel restrictions, shelter-in-place orders and shutdowns, business closures, cancellations of public gatherings and other measures. The extent and severity of the impact on the Company’s business and clinical trials will be determined largely by the extent to which there are disruptions in the supply chains for its research and product candidates, delays in the conduct of ongoing and future clinical trials, or reductions in the number of patients accessing AbbVie’s HCV regimens, or any combination of those events. During the second half of fiscal 2020 and through 2021, AbbVie experienced a decline in HCV sales compared to prior years as a result of a decline in patients accessing AbbVie’s HCV regimens due to the COVID-19 pandemic. This resulted in a decline in the Company’s royalty revenue earned for the years ended September 30, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.2241666666666668;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19 and public health actions taken to contain it, as well as the cumulative economic impact of both of those factors.</span></p>
CY2021	us-gaap	Year Founded YearFounded	1995
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.2241666666666668;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, management’s judgments with respect to its revenue arrangements; valuation of stock-based awards and the accrual of research and development expenses. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. The future developments of the COVID-19 pandemic also may directly or indirectly impact the Company’s business. The Company has made estimates of the impact of COVID-19 in the Company’s consolidated financial statements as of September 30, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Actual results could differ from the Company’s estimates.</span></p>
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	7151000
CY2021	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	0
CY2020	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	0
CY2019	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	0
CY2021Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	608000
CY2020Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	608000
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Concentration of Credit Risk and of Significant Customers and Suppliers</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities and accounts receivable. The Company has all cash and investment balances at one accredited financial institution, including cash in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has historically generated the majority of its revenue from its collaborative research and license agreements. As of September 30, 2021 and 2020, accounts receivable consisted of amounts due from the Company’s principal collaborator (see Note 7).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is completely dependent on third-party manufacturers for product supply for preclinical and clinical research activities. The Company relies and expects to continue to rely exclusively on several manufacturers to supply the Company with its drug supply requirements related to these activities. These research programs would be adversely affected by a significant interruption in the supply from these third-party manufacturers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
CY2020Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	413654000
CY2020Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	1479000
CY2021	enta	Fair Value Measurements Inter Transfers Between Levels FairValueMeasurementsInterTransfersBetweenLevels	0
CY2020	enta	Fair Value Measurements Inter Transfers Between Levels FairValueMeasurementsInterTransfersBetweenLevels	0
CY2019	enta	Fair Value Measurements Inter Transfers Between Levels FairValueMeasurementsInterTransfersBetweenLevels	0
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8622000
CY2021Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	350031000
CY2021Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	1506000
CY2021Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	295210000
CY2021Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	96000
CY2021Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	94000
CY2021Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	295212000
CY2020Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	330923000
CY2020Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1243000
CY2020Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	14000
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	332152000
CY2021Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	108416000
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	32634000
CY2021Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	24869000
CY2020Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	24270000
CY2021Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	18926000
CY2020Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15674000
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5943000
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8596000
CY2021Q3	enta	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	6062000
CY2020Q3	enta	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	5407000
CY2021Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6094000
CY2020Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4777000
CY2021Q3	enta	Accrued Liabilities Manufacturing AccruedLiabilitiesManufacturing	8402000
CY2020Q3	enta	Accrued Liabilities Manufacturing AccruedLiabilitiesManufacturing	2885000
CY2021Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	700000
CY2020Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1078000
CY2020Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	478000
CY2021Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1171000
CY2020Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	612000
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	22429000
CY2020Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14159000
CY2021Q3	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	558000
CY2020Q3	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	788000
CY2020Q3	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	290000
CY2021Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	558000
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2021Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q3	us-gaap	Preferred Stock Share Subscriptions PreferredStockShareSubscriptions	3000000
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	1093000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0061
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0141
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0276
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y18D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y7D
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y18D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.52
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.53
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.55
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	21.76
CY2020Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	30.47
CY2019Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	44.66
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3262000
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	49.82
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y6M
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	21860000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	901000
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	45.01
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	129000
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	27.99
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	182000
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	67.01
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3852000
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	48.61
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y4M24D
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	49173000
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3852000
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	48.61
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y4M24D
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	49173000
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2520000
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	45.91
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y2M12D
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	39356000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2704000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	7850000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	13855000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3614000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	10481000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6848000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	20991000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	19575000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	19226000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	20991000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	19575000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	19226000
CY2021Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	42222000
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y3M18D
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-78996000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-36168000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	46383000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20171000
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19940000
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19584000
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4297000
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3502000
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	2338000
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.81
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.21
CY2021	us-gaap	Lease Cost LeaseCost	9918000
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.92
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.81
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.37
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-78996000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-36168000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	46383000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20171000
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19940000
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19584000
CY2019	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	1384000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20171000
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19940000
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20968000
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.92
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	843000
CY2021	enta	Number Of Leases NumberOfLeases	2
CY2021	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	two options to extend the lease term for an additional three years each.
CY2019Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P18M
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	5861000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	3776000
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	4057000
CY2020	us-gaap	Lease Cost LeaseCost	6114000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	6364000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	4126000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3320000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3053000
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y5M4D
CY2020Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y2M12D
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0608
CY2020Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0650
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	4391000
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	675000
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	519000
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	0
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	0
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5585000
CY2021Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	256000
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	5329000
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4203000
CY2020Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4261000
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1126000
CY2020Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3838000
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	5329000
CY2020Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	8099000
CY2021Q3	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	608000
CY2020Q3	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	608000
CY2021Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	608000
CY2020Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	608000
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-28721000
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-8491000
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	1841000
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	205000
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-941000
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	372000
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	343000
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	8916000
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-2431000
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	1665000
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-608000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-28583000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1149000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-826000
CY2021	enta	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate1 EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate1	-0.210
CY2020	enta	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate1 EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate1	-0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.023
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.028
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.018
CY2021	enta	Effective Income Tax Rate Reconciliation Change In Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInValuationAllowance	0.099
CY2020	enta	Effective Income Tax Rate Reconciliation Change In Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInValuationAllowance	0.521
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.053
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.133
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.128
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.024
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.028
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.067
CY2021	enta	Effective Income Tax Rate Reconciliation Change In Deferred Tax Rate EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxRate	-0.095
CY2020	enta	Effective Income Tax Rate Reconciliation Change In Deferred Tax Rate EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxRate	-0.102
CY2019	enta	Effective Income Tax Rate Reconciliation Foreign Derived Intangible Income Percent EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent	-0.032
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.008
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.043
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.019
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.266
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.033
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.018
CY2021Q3	us-gaap	Income Tax Receivable IncomeTaxReceivable	37255000
CY2020Q3	us-gaap	Income Tax Receivable IncomeTaxReceivable	13041000
CY2020Q3	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	4657000
CY2020Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	345000
CY2021Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	1284000
CY2020Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	1598000
CY2021Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3095000
CY2020Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	861000
CY2021Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	378000
CY2020Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	245000
CY2021Q3	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	366000
CY2020Q3	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	444000
CY2021Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	31368000
CY2020Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	23261000
CY2020Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18259000
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-11039000
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-18259000
CY2021Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	29298000
CY2020Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18259000
CY2021Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	11843000
CY2020Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	11071000
CY2021Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	13170000
CY2020Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	6574000
CY2021Q3	enta	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	1232000
CY2020Q3	enta	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	2468000
CY2021Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	29298000
CY2020Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18259000
CY2021Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	2070000
CY2020Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	5002000
CY2021Q3	enta	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	1110000
CY2020Q3	enta	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	2221000
CY2021Q3	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	684000
CY2020Q3	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1650000
CY2021Q3	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	275000
CY2020Q3	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	364000
CY2021Q3	us-gaap	Deferred Tax Liabilities Other Comprehensive Income DeferredTaxLiabilitiesOtherComprehensiveIncome	1000
CY2020Q3	us-gaap	Deferred Tax Liabilities Other Comprehensive Income DeferredTaxLiabilitiesOtherComprehensiveIncome	422000
CY2021Q3	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2070000
CY2021	enta	Research And Development Tax Credit Carry Forward Expiration Year ResearchAndDevelopmentTaxCreditCarryForwardExpirationYear	2039
CY2021Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3095000
CY2021	enta	Deferred Tax Assets Operating Loss Carryforwards State Expiration Year DeferredTaxAssetsOperatingLossCarryforwardsStateExpirationYear	2040
CY2021Q3	enta	Deferred Tax Assets Liabilities Gross DeferredTaxAssetsLiabilitiesGross	29298000
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	11843000
CY2021Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	29298000
CY2021	us-gaap	Risks And Uncertainties In Entitys Business RisksAndUncertaintiesInEntitysBusiness	In response to the COVID-19 pandemic, the CARES Act was signed into law in March 2020. The CARES Act lifts certain deduction limitations originally imposed by the Tax Cuts and Jobs Act of 2017 (the “Tax Act”). Under the CARES Act, the Company is permitted to carryback net operating losses for up to five years for losses generated in fiscal 2018 through fiscal 2021. Net operating loss carrybacks were previously prohibited under the Tax Act. The CARES Act also eliminates the 80% of taxable income limitations by allowing corporate entities to fully utilize net operating loss carryforwards to offset taxable income in fiscal years 2018, 2019 or 2020. In addition, the CARES Act makes qualified improvement property eligible for 15-year cost-recovery and 100% bonus depreciation. The enactment of the CARES Act resulted in a $28,721 and $8,581 income tax benefit related to a federal net operating loss carryback at the previously enacted 35% rate in the Company’s consolidated financial statements during the years ended September 30, 2021 and 2020, respectively.
CY2021	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	28721000
CY2020	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	8581000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Percent EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent	0.35
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Percent EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent	0.35
CY2021Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	105000
CY2020Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	103000
CY2020Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	844000
CY2019Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1650000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	10000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	11000
CY2021	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	134000
CY2020	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	719000
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	98000
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	98000
CY2021Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	622000
CY2020Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	844000
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1353000
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1190000
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1068000

Files In Submission

Name	View Source	Status
0000950170-21-004895-index-headers.html	Edgar Link	pending
0000950170-21-004895-index.html	Edgar Link	pending
0000950170-21-004895.txt	Edgar Link	pending
0000950170-21-004895-xbrl.zip	Edgar Link	pending
enta-20210930.htm	Edgar Link	pending
enta-20210930.xsd	Edgar Link	pending
enta-20210930_cal.xml	Edgar Link	unprocessable
enta-20210930_def.xml	Edgar Link	unprocessable
enta-20210930_htm.xml	Edgar Link	completed
enta-20210930_lab.xml	Edgar Link	unprocessable
enta-20210930_pre.xml	Edgar Link	unprocessable
enta-ex10_28.htm	Edgar Link	pending
enta-ex21_1.htm	Edgar Link	pending
enta-ex23_1.htm	Edgar Link	pending
enta-ex31_1.htm	Edgar Link	pending
enta-ex31_2.htm	Edgar Link	pending
enta-ex32_1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
img214195130_0.jpg	Edgar Link	pending
img214195130_1.jpg	Edgar Link	pending
img214195130_2.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ENTA
ENANTA PHARMACEUTICALS INC Stock $enta

2021 Q3 Form 10-K Financial Statement

#000095017021004895 Filed on November 24, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENTA ENANTA PHARMACEUTICALS INC Stock $enta

2021 Q3 Form 10-K Financial Statement

#000095017021004895 Filed on November 24, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENTA
ENANTA PHARMACEUTICALS INC Stock $enta